Level A Evidence

4 Treatment Options Available

Advanced Heart Failure

Q: Who is a candidate for heart transplant?

Patients with end-stage heart failure (NYHA Class IV) with poor prognosis despite optimal medical therapy. Must pass comprehensive evaluation including cardiac, pulmonary, renal, infectious disease, and psychosocial assessments. Age typically <65-70 with good compliance.

Q: What is the difference between bridge and destination therapy VAD?

Bridge to transplant: VAD supports patient until a donor heart becomes available. Destination therapy: VAD is permanent treatment for patients ineligible for transplant. Both significantly improve survival and quality of life compared to medical therapy alone.

Q: How long is the wait for heart transplant?

Wait times vary based on blood type, size matching, and urgency status. In China, average wait is 1-3 months for suitable candidates. VAD can bridge patients during the wait.

Q: What is life like after heart transplant?

Most patients return to near-normal life within 3-6 months. Lifelong immunosuppression is required to prevent rejection. Regular monitoring includes biopsies, blood tests, and echo. Median survival is 12-14 years with modern immunosuppression.

VAD, ECMO & Heart Transplantation Services

Advanced heart failure is a debilitating condition where the heart cannot pump enough blood to meet the body's needs. When medical therapy fails, advanced options include mechanical circulatory support (ECMO, VAD) and heart transplantation. Our partner centers offer comprehensive heart failure programs with MCS capability and transplant services.

Condition Overview

Conditions We Treat

End-Stage Heart FailureCardiogenic ShockBridge to TransplantDestination Therapy VADPost-Cardiotomy Failure

Core Technologies

ECMO | LVAD (HeartMate, EVAHEART) | Heart transplantation | Cardiac resynchronization (CRT-D) | Inotrope therapy optimization

适宜人群

•End-stage heart failure requiring transplant evaluation
•Bridge to transplant with VAD
•Destination therapy VAD
•Cardiogenic shock requiring ECMO
•Complex heart failure needing specialized care

Comprehensive heart failure centers with transplant programs

建议在本地考虑

•Stable chronic heart failure on oral medications
•Routine heart failure clinic follow-up
•Cardiac resynchronization therapy
•Cases with established local heart failure team

Stable patients with good local cardiology support

Evidence: Partner centers >100 heart transplants/year; 1-year survival >85%; VAD 1-year survival >80%; ECMO weaning rate 60%.

Treatment Options

Heart Transplantation

手术

适合：End-stage heart failure, suitable candidate

技术：Orthotopic heart transplant, bicaval technique

优势：Gold standard for end-stage heart failure

21-30 daysFrom $80,000

>100 transplants/year at top centers

Left Ventricular Assist Device (LVAD)

手术

适合：Bridge to transplant or destination therapy

技术：Continuous flow device (HeartMate, EVAHEART)

优势：Improves survival and quality of life

14-21 daysFrom $50,000

Experienced MCS programs

ECMO (Extracorporeal Membrane Oxygenation)

介入

适合：Cardiogenic shock, bridge to recovery/decision

技术：VA-ECMO for cardiac support

优势：Life support for critical patients

VariableFrom $15,000

24/7 ECMO capability

Cardiac Resynchronization Therapy (CRT-D)

介入

适合：Heart failure with dyssynchrony, wide QRS

技术：Biventricular pacemaker with defibrillator

优势：Improves symptoms, reduces hospitalization

2-3 daysFrom $12,000

Standard electrophysiology service

费用对比

Heart Transplantation

US Hospital$350,000

UK Private$250,000

MediLink China$100,000

Save 71% vs US • Includes: transplant surgery, 3-4 week hospitalization, initial immunosuppression

计算费用

治疗流程

Evaluation• Week 1-2

Comprehensive heart failure workup
Right heart catheterization
Transplant evaluation (multidisciplinary)
Psychosocial assessment

Treatment• Week 3-8

Transplant or VAD implantation
ICU recovery (1-2 weeks)
Immunosuppression management
Rehabilitation initiation

Long-term Care• Years 1-Lifetime

Lifelong immunosuppression (transplant)
Anticoagulation (VAD)
Regular biopsies (transplant)
Cardiac rehabilitation

Clinical Outcomes

1-Year Survival (Transplant)

85%+

national average

5-Year Survival (Transplant)

70%

after transplant

LVAD 1-Year Survival

80%

destination therapy

Infection Rate

<15%

first year post-transplant

常见问题

Who is a candidate for heart transplant?

Patients with end-stage heart failure (NYHA Class IV) with poor prognosis despite optimal medical therapy. Must pass comprehensive evaluation including cardiac, pulmonary, renal, infectious disease, and psychosocial assessments. Age typically <65-70 with good compliance.

What is the difference between bridge and destination therapy VAD?

Bridge to transplant: VAD supports patient until a donor heart becomes available. Destination therapy: VAD is permanent treatment for patients ineligible for transplant. Both significantly improve survival and quality of life compared to medical therapy alone.

How long is the wait for heart transplant?

Wait times vary based on blood type, size matching, and urgency status. In China, average wait is 1-3 months for suitable candidates. VAD can bridge patients during the wait.

What is life like after heart transplant?

Most patients return to near-normal life within 3-6 months. Lifelong immunosuppression is required to prevent rejection. Regular monitoring includes biopsies, blood tests, and echo. Median survival is 12-14 years with modern immunosuppression.